Meeting
2018 ASCO Annual Meeting
A phase II trial of stereotactic body radiation therapy for operable T1N0M0 non-small cell lung cancer: Japan Clinical Oncology Group (JCOG0403)—Long term follow-up results.
Authors
Yasushi Nagata
Hiroshima Univ Hosp, Hiroshima, Japan
Yasushi Nagata , Masahiro Hiraoka , Taro Shibata , Hiroshi Onishi , Masaki Kokubo , Katsuyuki Karasawa , Yoshiyuki Shioyama , Rikiya Onimaru , Etsuo Kunieda , Satoshi Ishikura
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT00238875
Citation
J Clin Oncol 36, 2018 (suppl; abstr 8512)
DOI
10.1200/JCO.2018.36.15_suppl.8512
Abstract #
8512
Poster Bd #
118
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
A phase II trial of second-line erlotinib in combination with stereotactic body radiation therapy (SBRT) for patients with metastatic non-small cell lung cancer (NSCLC).
First Author: Puneeth Iyengar
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase II trial of combination of PD-1 immune checkpoint inhibition with all-lesion stereotactic radiation (SBRT) in oligometastatic renal cell carcinoma (omRCC).
First Author: Jing Liu
Poster
2023 ASCO Gastrointestinal Cancers Symposium
NET-02 final results: A randomised, phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line (2L) therapy in patients (pts) with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (PD-EP-NEC).
First Author: Mairead Geraldine McNamara
Poster
2022 ASCO Annual Meeting
Randomized study to investigate a switch maintenance concept with 5-FU plus bevacizumab after FOLFIRI plus cetuximab induction treatment versus continued treatment with FOLFIRI plus cetuximab: Report of a secondary endpoint of the phase-III FIRE-4 study (AIO KRK-0114).
First Author: Sebastian Stintzing